Before joining Alkalos in 2017, he was VP of Corporate Development at ZS Pharma, and later promoted to Chief Scientific Officer. ZS Pharma is a specialty pharmaceutical company focused on the research and development of highly selective ion-trap therapies to treat serious medical conditions.
Adam spent 7 years at Alta partners focused on life science investments. Originally trained as an organic and medicinal chemist, Adam spent the previous 7 years in early-stage drug discovery with Gilead Sciences and Cytokinetics. In his last technical position, he founded and led the Anti-Infectives Medicinal Chemistry Program at Cytokinetics, which was the first group to validate KIP-1 as an anti-fungal target. Adam also played a key role in the creation of Cytokinetics' cardiovascular drug CK-1827452, currently in clinical trials.
Earlier, Adam was a student in the Harvard-MIT Biomedical Enterprise Program; he completed internships at MPM Capital and Lehman Brothers, where he was an Analyst covering the biotech sector, and attended the Harvard Medical School.
Education, Personal, and Fellowship
Adam holds a Bachelor of Science in chemistry from the University of California, Berkeley, a and an MBA from the MIT Sloan School of Management. He completed his PhD at the University of California, Irvine, where he was a Fellow of the American Chemical Society and the University of California Regents, and was a post doctoral student with Peter Schultz at The Scripps Research Institute/The Genomics Institute of the Novartis Foundation.
Adam completed his fellowship at Alta Partners in San Francisco under mentor Dan Janney as a member of Fellows Class 11.